pI: 7.4323 |
Length (AA): 281 |
MW (Da): 29671 |
Paralog Number:
0
Signal peptide: Y | GPI Anchor: | Predicted trans-membrane segments: 1
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 3 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
12 | 281 | 2jbw (A) | 71 | 354 | 17.00 | 0.00016 | 1 | 1.14355 | -0.01 |
51 | 167 | 4j7a (A) | 86 | 212 | 20.00 | 0.47 | 1 | 0.72707 | -0.99 |
216 | 275 | 2hdw (A) | 308 | 365 | 43.00 | 0.29 | 0.96 | 0.620323 | 0.42 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 20-40% percentile | Dormant phase, Dormant phase. | hasan murphy |
murphy | Identification of gene targets against dormant phase Mycobacterium tuberculosis infections. |
hasan | Prioritizing genomic drug targets in pathogens: application to Mycobacterium tuberculosis. |
Ortholog group members (OG5_128284)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT5G20520 | Bem46-family protein WAV2 |
Candida albicans | CaO19.7627 | similar to S. cerevisiae YNL320W |
Cryptosporidium hominis | Chro.30101 | RIKEN cDNA 1110065L07 |
Cryptosporidium parvum | cgd3_730 | conserved expressed protein |
Dictyostelium discoideum | DDB_G0289671 | hypothetical protein |
Drosophila melanogaster | Dmel_CG18642 | CG18642 gene product from transcript CG18642-RA |
Escherichia coli | b2534 | putative S9 family prolyl oligopeptidase |
Echinococcus granulosus | EgrG_001178900 | abhydrolase domain containing protein 13 |
Entamoeba histolytica | EHI_011810 | hypothetical protein, conserved |
Entamoeba histolytica | EHI_037210 | hypothetical protein |
Echinococcus multilocularis | EmuJ_001178900 | abhydrolase domain containing protein 13 |
Homo sapiens | ENSG00000139826 | abhydrolase domain containing 13 |
Leishmania braziliensis | LbrM.34.4000 | Bem46-like serine peptidase,Serine peptidase, Clan SC, Family S09X |
Leishmania donovani | LdBPK_354070.1 | Bem46-like serine peptidase |
Leishmania infantum | LinJ.35.4070 | Bem46-like serine peptidase,Serine peptidase, Clan SC, Family S09X |
Leishmania major | LmjF.35.4020 | Bem46-like serine peptidase,Serine peptidase, Clan SC, Family S09X |
Leishmania mexicana | LmxM.34.4020 | Bem46-like serine peptidase,Serine peptidase, Clan SC, Family S09X |
Mus musculus | ENSMUSG00000040396 | abhydrolase domain containing 13 |
Mycobacterium tuberculosis | Rv2307c | Conserved hypothetical protein |
Neospora caninum | NCLIV_008960 | hypothetical protein |
Oryza sativa | 4343867 | Os07g0608300 |
Plasmodium berghei | PBANKA_0712200 | BEM46-like protein, putative |
Plasmodium falciparum | PF3D7_0818600 | BEM46-like protein, putative |
Plasmodium knowlesi | PKNH_0501300 | BEM46-like protein, putative |
Plasmodium vivax | PVX_089485 | hypothetical protein, conserved |
Plasmodium yoelii | PY06542 | unnamed protein product |
Saccharomyces cerevisiae | YNL320W | hypothetical protein |
Schmidtea mediterranea | mk4.047423.00 | |
Schmidtea mediterranea | mk4.022783.00 | |
Trypanosoma brucei gambiense | Tbg972.9.6490 | Bem46-like serine peptidase,Serine peptidase, Clan SC, Family S09X |
Trypanosoma brucei | Tb927.9.10970 | Serine peptidase, Clan SC, Family S09X |
Trypanosoma congolense | TcIL3000_9_4500 | Bem46-like serine peptidase |
Trypanosoma congolense | TcIL3000_9_4480 | Bem46-like serine peptidase |
Trypanosoma cruzi | TcCLB.508461.260 | Serine peptidase, Clan SC, Family S09X, putative |
Toxoplasma gondii | TGME49_254690 | phospholipase/carboxylesterase |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
mtu2343 this record | Mycobacterium tuberculosis | non-essential | nmpdr |
Tb09.211.2310 | Trypanosoma brucei | significant gain of fitness in bloodstream forms (3 days) | alsford |
Tb09.211.2310 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb09.211.2310 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb09.211.2310 | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
b2534 | Escherichia coli | non-essential | goodall |
PBANKA_0712200 | Plasmodium berghei | Dispensable | plasmo |
TGME49_254690 | Toxoplasma gondii | Probably non-essential | sidik |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.